CVM

$3.60

Market ClosedAs of Mar 17, 8:00 PM UTC

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Recent News

Associated Press Finance
Feb 17, 2026

Cel-Sci: Fiscal Q1 Earnings Snapshot

VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Tuesday reported a loss of $5.5 million in its fiscal first quarter.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Associated Press Finance
Aug 14, 2025

Cel-Sci: Fiscal Q3 Earnings Snapshot

VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Thursday reported a loss of $5.7 million in its fiscal third quarter.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Associated Press Finance
May 14, 2025

Cel-Sci: Fiscal Q2 Earnings Snapshot

VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Wednesday reported a loss of $6.6 million in its fiscal second quarter.

BEARISH
Negative press. News cycle fixated on risk factors or misses.